Authors: Emanuela Senjor, Simona Miceska, Biljana Mileva Boshkoska, Tanja Mesti, Janja Ocvirk, Janko Kos, Milica Perišić Nanut
Summary
New research suggests that monitoring the expression of Cystatin F in cytotoxic T lymphocytes (CTLs) could serve as a valuable, dynamic biomarker to predict the effectiveness of immune checkpoint inhibitor (ICI) therapy in melanoma patients. The study titled “Immune Checkpoint Inhibitors Modulate Cystatin F Expression in Cytotoxic T Cells from Melanoma Patients” found that patients who responded favorably to ICI treatment showed a progressive decrease in Cystatin F levels in their circulating CTLs.
Background: The Need for Better Biomarkers
Despite the revolutionary impact of immune checkpoint inhibitors (ICIs) like nivolumab and pembrolizumab in cancer treatment, a significant portion of patients—over 60%—do not respond. Even initial responders often face resistance mechanisms, underscoring a critical need for reliable biomarkers to identify which patients will benefit, thereby optimizing treatment and reducing costs and potential adverse events.
A central challenge lies in the dysfunction of Cytotoxic T Lymphocytes (CTLs), the very immune cells ICIs aim to unleash. CTLs eliminate cancer cells by deploying cytotoxic molecules, such as perforin and granzymes, which require activation by specific enzymes called cathepsins.
Cystatin F is a potent endogenous inhibitor of these cathepsins, making it a negative regulator of CTL cytotoxic function. Elevated Cystatin F is linked to reduced killing capacity in immune cells, a state known as “split anergy.” Previous preliminary data even suggested that anti-PD-1 treatment might upregulate Cystatin F, hinting at a connection between ICI therapy and the modulation of CTL effectiveness.
Study Design and Methods
Researchers conducted a longitudinal analysis of peripheral blood samples from melanoma patients receiving first-line ICI therapy (nivolumab, ipilimumab/nivolumab, or pembrolizumab) at the Institute of Oncology Ljubljana.
Samples were collected at three crucial timepoints:
- Four weeks prior to treatment initiation.
- 12 weeks post-initiation.
- 28 weeks post-initiation.
Patients were monitored for up to 12 months and stratified into responder and non-responder groups based on clinical criteria. The team isolated CTLs from the peripheral blood mononuclear cells (PBMCs) and employed a multimodal approach to analyze Cystatin F:
- Flow cytometry was used to quantify intracellular Cystatin F protein expression in CTLs.
- qRT-PCR measured the transcript levels of Cystatin F and other cytolytic effector genes (perforin, granzymes).
- Western blot assessed the expression and activation state of key cytotoxic granule components.
Key Findings: Cystatin F Declines with Response
The core finding of the study revealed a significant correlation: Cystatin F expression in CTLs progressively declined in melanoma patients who responded to ICI therapy.
This temporal decrease was most notable in individuals who achieved durable clinical responses. This observation leads to the conclusion that elevated Cystatin F may be a marker of impaired, dysfunctional CTLs prior to or early during treatment, while its subsequent downregulation reflects the successful restoration or enhancement of cytolytic activity essential for tumor clearance.
Conclusion and Future Outlook
These results underscore the clinical relevance of monitoring Cystatin F expression in peripheral CTLs throughout the course of ICI therapy. As a key regulator of cytotoxic immune function, Cystatin F offers promise as a dynamic indicator of therapeutic efficacy and disease progression in melanoma.
The authors conclude that incorporating Cystatin F into existing biomarker panels could significantly enhance patient stratification, allowing clinicians to tailor treatment strategies more effectively. Future research will focus on validating these findings across broader patient populations and fully elucidating the molecular mechanisms driving Cystatin F modulation following immune checkpoint blockade
